Shares digital

GW Pharmaceuticals (GWP:AIM) – Finals PTP: -£13m (-15.3m) Divi: n/a (n/a)

Losses narrowed at the drug development company, helped by a 185% increase in turnover to £5.7 million. This year is a pivotal one for the company with three major Phase III trials for its cannabis-based Sativex products due to report in 2008. Sativex is already approved for cancer pain relief in Canada, generating revenues, but it is carrying out more trials to try to gain approval for MS spasticity, MS neuropathic pain and cancer pain in Europe and the US. Positive results from any of these would be a massive boost but delays have weighed heavy on investor sentiment in the past. It has a healthy cash pile of £21 million to see it through trials.

Shares says: It is worth holding on to the shares as it only needs success in one area to provide a real fillip.

by: Susanna Twidale